Kura Oncology Inc (NASDAQ: KURA)’s stock price has soared by 1.62 in relation to previous closing price of 6.81. Nevertheless, the company has seen a gain of 7.29% in its stock price over the last five trading days. zacks.com reported 2025-06-06 that Kura Oncology shares rise this week after the FDA accepts its NDA for ziftomenib, a potential first-in-class treatment for NPM1-mutant AML.
Is It Worth Investing in Kura Oncology Inc (NASDAQ: KURA) Right Now?
Moreover, the 36-month beta value for KURA is 0.41. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for KURA is 82.28M and currently, short sellers hold a 10.16% of that float. On June 12, 2025, KURA’s average trading volume was 1.28M shares.
KURA’s Market Performance
The stock of Kura Oncology Inc (KURA) has seen a 7.29% increase in the past week, with a 13.63% rise in the past month, and a -10.25% fall in the past quarter. The volatility ratio for the week is 1.00%, and the volatility levels for the past 30 days are at 3.84% for KURA. The simple moving average for the last 20 days is 11.61% for KURA’s stock, with a simple moving average of -37.63% for the last 200 days.
Analysts’ Opinion of KURA
UBS, on the other hand, stated in their research note that they expect to see KURA reach a price target of $27. The rating they have provided for KURA stocks is “Buy” according to the report published on October 24th, 2024.
Stifel gave a rating of “Hold” to KURA, setting the target price at $19 in the report published on October 14th of the previous year.
KURA Trading at 12.59% from the 50-Day Moving Average
After a stumble in the market that brought KURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.53% of loss for the given period.
#####
#####
Insider Trading
Reports are indicating that there were more than several insider trading activities at KURA starting from Bair Teresa Brophy, who sale 1,559 shares at the price of $5.96 back on May 19 ’25. After this action, Bair Teresa Brophy now owns 107,948 shares of Kura Oncology Inc, valued at $9,292 using the latest closing price.
FORD KATHLEEN, the Chief Operating Officer of Kura Oncology Inc, sale 1,558 shares at $6.28 during a trade that took place back on May 19 ’25, which means that FORD KATHLEEN is holding 21,367 shares at $9,777 based on the most recent closing price.
Stock Fundamentals for KURA
Current profitability levels for the company are sitting at:
- -2.99 for the present operating margin
- 0.99 for the gross margin
The net margin for Kura Oncology Inc stands at -2.68. The total capital return value is set at -0.31. Equity return is now at value -41.84, with -28.03 for asset returns.
Based on Kura Oncology Inc (KURA), the company’s capital structure generated 0.05 points at debt to capital in total, while cash flow to debt ratio is standing at 5.75. The debt to equity ratio resting at 0.05. The interest coverage ratio of the stock is -166.62.
Currently, EBITDA for the company is -169.5 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of 8.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.07.
Conclusion
To wrap up, the performance of Kura Oncology Inc (KURA) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
